Amicus, Biogen enter multi-year agreement in Parkinson's
Executive Summary
Just a day after signing its fourth antisense neurology deal with Isis Pharmaceuticals, Biogen Idec Inc. penned a multi-year agreement with rare disease drug company Amicus Therapeutics Inc. for the discovery, development, and commercialization of small molecules for Parkinson's disease (PD).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice